Lysophosphatidic acid protection against apoptosis in the human pre-B-cell line Nalm-6
Yumiko Satoh
Department of Clinical Laboratory, The University of Tokyo Hospital
Department of Molecular Oncology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University
Search for more papers by this authorRyunosuke Ohkawa
Department of Clinical Laboratory, The University of Tokyo Hospital
Search for more papers by this authorKazuhiro Nakamura
Department of Clinical Laboratory, The University of Tokyo Hospital
Search for more papers by this authorKatsumi Higashi
Department of Clinical Laboratory, The University of Tokyo Hospital
Search for more papers by this authorMakoto Kaneko
Department of Clinical Laboratory, The University of Tokyo Hospital
Search for more papers by this authorHiromitsu Yokota
Department of Clinical Laboratory, The University of Tokyo Hospital
Search for more papers by this authorJunken Aoki
Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo
PRESTO, Japan Science and Technology Corporation
Search for more papers by this authorHiroyuki Arai
Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo
Search for more papers by this authorYasuhito Yuasa
Department of Molecular Oncology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University
Search for more papers by this authorYutaka Yatomi
Department of Clinical Laboratory, The University of Tokyo Hospital
Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Search for more papers by this authorYumiko Satoh
Department of Clinical Laboratory, The University of Tokyo Hospital
Department of Molecular Oncology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University
Search for more papers by this authorRyunosuke Ohkawa
Department of Clinical Laboratory, The University of Tokyo Hospital
Search for more papers by this authorKazuhiro Nakamura
Department of Clinical Laboratory, The University of Tokyo Hospital
Search for more papers by this authorKatsumi Higashi
Department of Clinical Laboratory, The University of Tokyo Hospital
Search for more papers by this authorMakoto Kaneko
Department of Clinical Laboratory, The University of Tokyo Hospital
Search for more papers by this authorHiromitsu Yokota
Department of Clinical Laboratory, The University of Tokyo Hospital
Search for more papers by this authorJunken Aoki
Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo
PRESTO, Japan Science and Technology Corporation
Search for more papers by this authorHiroyuki Arai
Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, The University of Tokyo
Search for more papers by this authorYasuhito Yuasa
Department of Molecular Oncology, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University
Search for more papers by this authorYutaka Yatomi
Department of Clinical Laboratory, The University of Tokyo Hospital
Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Search for more papers by this authorAbstract
Lysophosphatidic acid (LPA) promotes survival, growth, differentiation, and motility in a variety of cell types, and has been reported to act as a cell survival and growth factor in B lymphocytes. Autotaxin (ATX), through its lysophospholipase D activity, generates LPA from lysophosphatidylcholine (LPC). In this study, we investigated the effects of LPA and also the expression of ATX and LPA receptor, in the human pre-B-cell line Nalm-6. It was found that LPA protects Nalm-6 cells against both spontaneous and staurosporine-induced apoptosis. Furthermore, ATX expression on the cell surface and ATX activity in the cell lysate were detected. No accumulation of LPA in the culture medium was, however, detected when the Nalm-6 cells were cultured with LPC. The pre-B cells were found to express the mRNA transcript for lipid phosphate phosphatase-1 and LPA degradation was inhibited in the presence of the phosphatase inhibitor vanadate, it was surmised that LPA production in the culture medium may have been masked by LPA degradation by this ecto-phosphatase. Abundant expression of LPA receptors, especially, LPA4, was detected by a real-time polymerase chain reaction technique. Our results suggest an important and autocrine role of LPA in the survival of this well-established model cell line, although the direct involvement of ATX in the production of LPA in these cells was not confirmed.
References
- 1 Tokumura A. A family of phospholipid autacoids: occurrence, metabolism and bioactions. Prog Lipid Res 1995; 34: 151–84.
- 2 Moolenaar WH. Bioactive lysophospholipids and their G protein-coupled receptors. Exp Cell Res 1999; 253: 230–8.
- 3 Anliker B, Chun J. Lysophospholipid G protein-coupled receptors. J Biol Chem 2004; 279: 20555–8.
- 4 Hu X, Haney N, Kropp D, Kabore AF, Johnston JB, Gibson SB. Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB. J Biol Chem 2005; 280: 9498–508.
- 5 Gerrard JM, Robinson P. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim Biophys Acta 1989; 1001: 282–5.
- 6 Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993; 291(Pt 3): 677–80.
- 7 Shen Z, Belinson J, Morton RE, Xu Y, Xu Y. Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells. Gynecol Oncol 1998; 71: 364–8.
- 8 Croset M, Brossard N, Polette A, Lagarde M. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem J 2000; 345(Pt 1): 61–7.
- 9
Okita M,
Gaudette DC,
Mills GB,
Holub BJ.
Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients.
Int J Cancer
1997; 71: 31–4.
10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4 CAS PubMed Web of Science® Google Scholar
- 10 Tokumura A, Fujimoto H, Yoshimoto O, Nishioka Y, Miyake M, Fukuzawa K. Production of lysophosphatidic acid by lysophospholipase D in incubated plasma of spontaneously hypertensive rats and Wistar Kyoto rats. Life Sci 1999; 65: 245–53.
- 11 Umezu-Goto M, Kishi Y, Taira A, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002; 158: 227–33.
- 12 Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, Fukuzawa K. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002; 277: 39436–42.
- 13 Bandoh K, Aoki J, Hosono H, Kobayashi S, Kobayashi T, Murakami-Murofushi K, Tsujimoto M, Arai H, Inoue K. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem 1999; 274: 27776–85.
- 14 Nam SW, Clair T, Kim YS, McMarlin A, Schiffmann E, Liotta LA, Stracke ML. Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor. Cancer Res 2001; 61: 6938–44.
- 15 Kanno S, Uwai K, Tomizawa A, Hiura T, Osanai Y, Ujibe M, Takeshita M, Ohtake T, Kimura K, Ishikawa M. Trimidox induces apoptosis via cytochrome c release in NALM-6 human B cell leukaemia cells. Basic Clin Pharmacol Toxicol 2006; 98: 44–50.
- 16 Garcia-Gila M, Lopez-Martin EM, Garcia-Pardo A. Adhesion to fibronectin via alpha4 integrin (CD49d) protects B cells from apoptosis induced by serum deprivation but not via IgM or Fas/Apo-1 receptors. Clin Exp Immunol 2002; 127: 455–62.
- 17 Nilsson J, Soderberg O, Nilsson K, Rosen A. Differentiation-associated redox-regulation in human B cell lines from stem cell/pro-B to plasma cell. Immunol Lett 2004; 94: 83–9.
- 18 Tanaka M, Kishi Y, Takanezawa Y, Kakehi Y, Aoki J, Arai H. Prostatic acid phosphatase degrades lysophosphatidic acid in seminal plasma. FEBS Lett 2004; 571: 197–204.
- 19 Kishimoto T, Soda Y, Matsuyama Y, Mizuno K. An enzymatic assay for lysophosphatidylcholine concentration in human serum and plasma. Clin Biochem 2002; 35: 411–6.
- 20 Kishimoto T, Matsuoka T, Imamura S, Mizuno K. A novel colorimetric assay for the determination of lysophosphatidic acid in plasma using an enzymatic cycling method. Clin Chim Acta 2003; 333: 59–67.
- 21 Sun Y, Orrenius S, Pervaiz S, Fadeel B. Plasma membrane sequestration of apoptotic protease-activating factor-1 in human B-lymphoma cells: a novel mechanism of chemoresistance. Blood 2005; 105: 4070–7.
- 22 Brindley DN, English D, Pilquil C, Buri K, Ling ZC. Lipid phosphate phosphatases regulate signal transduction through glycerolipids and sphingolipids. Biochim Biophys Acta 2002; 1582: 33–44.
- 23 Kai M, Wada I, Imai S, Sakane F, Kanoh H. Cloning and characterization of two human isozymes of Mg2+-independent phosphatidic acid phosphatase. J Biol Chem 1997; 272: 24572–8.
- 24 Sciorra VA, Morris AJ. Roles for lipid phosphate phosphatases in regulation of cellular signaling. Biochim Biophys Acta 2002; 1582: 45–51.
- 25 Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3: 582–91.
- 26 Tokumura A. Physiological and pathophysiological roles of lysophosphatidic acids produced by secretory lysophospholipase D in body fluids. Biochim Biophys Acta 2002; 1582: 18–25.
- 27 Brindley DN. Lipid phosphate phosphatases and related proteins: signaling functions in development, cell division, and cancer. J Cell Biochem 2004; 92: 900–12.
- 28 Hecht JH, Weiner JA, Post SR, Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol 1996; 135: 1071–83.
- 29 An S, Bleu T, Hallmark OG, Goetzl EJ. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem 1998; 273: 7906–10.
- 30 Hama K, Aoki J, Fukaya M, et al. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem 2004; 279: 17634–9.
- 31 Moolenaar WH, Van Meeteren LA, Giepmans BN. The ins and outs of lysophosphatidic acid signaling. Bioessays 2004; 26: 870–81.
- 32 Noguchi K, Ishii S, Shimizu T. Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem 2003; 278: 25600–6.
- 33 Tanyi JL, Morris AJ, Wolf JK, et al. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res 2003; 63: 1073–82.
- 34 Tanyi JL, Hasegawa Y, Lapushin R, et al. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res 2003; 9: 3534–45.
- 35 Baumforth KR, Flavell JR, Reynolds GM, et al. Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood 2005; 106: 2138–46.
- 36 Aoki S, Yatomi Y, Ohta M, Osada M, Kazama F, Satoh K, Nakahara K, Ozaki Y. Sphingosine 1-phosphate-related metabolism in the blood vessel. J Biochem (Tokyo) 2005; 138: 47–55.
Citing Literature
